<SEC-DOCUMENT>0001140361-23-024137.txt : 20250909
<SEC-HEADER>0001140361-23-024137.hdr.sgml : 20250909
<ACCEPTANCE-DATETIME>20230511161118
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001140361-23-024137
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NorthView Acquisition Corp
		CENTRAL INDEX KEY:			0001859807
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				863437271
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		207 WEST 25TH ST, 9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		212-494-9022

	MAIL ADDRESS:	
		STREET 1:		207 WEST 25TH ST, 9TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NorthView Acquisition Corp
		DATE OF NAME CHANGE:	20210429
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8a7b3469c874411ea5645ccea7ae44af" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td rowspan="3" style="width: 70%; vertical-align: top;"><img src="ny20006207x3_logo.jpg"></td>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">ArentFox Schiff LLP</div>
            <div>1717 K Street NW<br>
              Washington, DC&#160; 20006</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div> <br>
              </div>
              <div>202.857.6000&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-variant: small-caps; font-weight: bold;">main</font></div>
            </div>
            <div>
              <div>202.857.6395&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-variant: small-caps; font-weight: bold;">fax</font></div>
              <div>&#160;</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif; color: rgb(234, 2, 7);"> <br>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif; color: rgb(234, 2, 7);">afslaw.com</div>
            <div style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);"> <br>
            </div>
            <div style="font-weight: bold;">Ralph De Martino</div>
            <div>Partner</div>
            <div>(202) 724-6848&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-variant: small-caps; font-weight: bold;">direct</font></div>
            <div>rdemartino@afslaw.com</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>May 11, 2023</div>
    <div><br>
    </div>
    <div>Office of Industrial Applications and Services</div>
    <div>Division of Corporation Finance</div>
    <div style="text-align: justify;">United States Securities and Exchange Commission</div>
    <div style="text-align: justify;">100 F St NE</div>
    <div style="text-align: justify;">Washington, DC 20549</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf6a52b97f1bd405da6abcae390beb125" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top;">
            <div>Attention:</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div>Jane Park</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;">&#160;</td>
          <td style="width: 94%; vertical-align: top;">
            <div>Celeste Murphy</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-indent: -18pt; margin-left: 18pt; font-weight: bold;">Re: NorthView Acquisition Corporation Registration</div>
    <div style="text-indent: -18pt; margin-left: 18pt; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160; Statement on Form S-4 Filed January 25, 2023</div>
    <div style="text-indent: -18pt; margin-left: 18pt; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160; File No. 333-269417</div>
    <div><br>
    </div>
    <div style="text-align: justify;">To Whom It May Concern:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The undersigned serves as counsel to NorthView Acquisition Corporation (&#8220;NorthView&#8221; or the &#8220;Company&#8221;). Contemporaneous with the submission of this correspondence, NorthView filed its Amendment No. 1 (the &#8220;Amendment&#8221;)
      to its Registration Statement on Form S-4 filed on January 25, 2023 (File No. 333-269417). Pursuant to the comments by the staff (the &#8220;Staff&#8221;) of the Division of Corporation Finance of the United States Securities and Exchange Commission (the
      &#8220;Commission&#8221;), set forth in its letter dated February 21, 2023 (the &#8220;Comment Letter&#8221;), and addressed to Jack Stover, Chief Executive Officer of NorthView, the Amendment responds to the Staff&#8217;s comments included in the Comment Letter. For the
      convenience of the Staff, the comments included in the Comment Letter are posted below (in bold) and NorthView&#8217;s response follows each comment.</div>
    <div><br>
    </div>
    <div style="margin-left: 8pt; font-weight: bold;"><u>Form S-4 Filed January 25, 2023 Cover Page</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z75aecfd6dff04eb3815538c576ec6f10" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please revise the prospectus cover page to disclose the expected ownership percentages in the combined company of NorthView&#8217;s public stockholders, the Sponsor and its affiliates and Profusa stockholders. To the
              extent applicable, disclose the total expected ownership of the Sponsor following the transaction, inclusive of any investments the Sponsor plans to make through financing transactions, such as the PIPE investment.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosure on the cover page to include the requested information.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table id="zc3514c666ad048b687c5884cd5b32d25" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 2</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 8pt; font-weight: bold;"><u>Questions and Answers about the Business Combination, page xi</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1035514fa25944438399f77ff6dcae4c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please revise to disclose all possible sources and extent of dilution that shareholders who elect not to redeem their shares may experience in connection with the business combination. Provide disclosure of the
              impact of each significant source of dilution, including the amount of equity held by founders, convertible securities, including warrants retained by redeeming shareholders, at each of the redemption levels detailed in your sensitivity
              analysis, including any needed assumptions.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 41.8pt;"><u>RESPONSE</u>: We have amended the disclosures on pages xi and xiii to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z320b522941cb43c3ae93a27cef7f2d29" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please revise your disclosure in this section and elsewhere in the prospectus as appropriate to highlight the material risks to public warrant holders, including those arising from differences between private and
              public warrants. Clarify whether recent common stock trading prices exceed the threshold that would allow the company to redeem public warrants. Clearly explain the steps, if any, the company would take to notify all shareholders, including
              beneficial owners, regarding when the warrants become eligible for redemption.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages xi and xiii to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Q: What equity stake will current NorthView stockholders and current Profusa stockholders hold in the combined company...?, page xii</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zde77704c683e4b9bb0c749659f719bb0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please disclose the Sponsor and its affiliates&#8217; total potential ownership interest in the combined company, assuming exercise and conversion of all securities.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page xiii to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc1aa7474f3b548d5b03e90763e33be93" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Revise your disclosure to show the potential impact of redemptions on the per share value of the shares owned by non-redeeming shareholders by including a sensitivity analysis showing a range of redemption
              scenarios, including at least one interim redemption level.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: The Company respectfully submits to the Staff that, subsequent to the filing of the initial Registration Statement, the Company experienced stockholder redemptions such that the impact of any interim
      redemption level does not appear to be material relative to the No Redemption and Maximum Redemption scenarios and presented in the amended disclosures. However, we have amended the disclosures on page xiii to include the requested information with
      the exception of the presentation of an interim redemption level.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z12e86e3f0e4d4cc3ac615f750838de13" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please revise to disclose all possible sources and extent of dilution that shareholders who elect not to redeem their shares may experience in connection with the business combination. Provide disclosure of the
              impact of each significant source of dilution, including the amount of equity held by founders, convertible securities, including warrants retained by redeeming shareholders, at each of the redemption levels detailed in your sensitivity
              analysis, including any needed assumptions.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page xiii to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z769249cce2b24a19bd0c788fa307a853" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">7.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please clarify, if true, that the sponsor will receive additional securities pursuant to an anti-dilution adjustment based on the company&#8217;s additional financing activities. If applicable, please quantify the
              number and value of securities the sponsor will receive. In addition, disclose the ownership percentages in the company before and after the additional financing to highlight dilution to public stockholders.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We advise the Staff that Sponsor will not receive additional securities pursuant to an anti-dilution adjustment based on the company&#8217;s additional financing activities.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 3<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Q: Do I have redemption rights?, page xvii</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z72fa11152f514304bccb31c5c8b1dd63" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Clarify, if true, that holders of your public warrants and holders of warrants through your units cannot exercise redemption rights with respect to the warrants. Quantify the value of warrants, based on recent
              trading prices, that may be retained by redeeming stockholders assuming maximum redemptions and identify any material resulting risks.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page xix to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Summary of the Proxy Statement/Prospectus, page 1</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8774dcc97a8246968022ebc1179f18c7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">9.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please revise to expand your descriptions of NorthView and Profusa in this section. Please discuss the types of products and services Profusa provides, how the company generates revenue, and when the company
              commenced work designing these products and obtained CE approval. Revise to include disclosure that Profusa&#8217;s products are currently categorized as Class III medical devices and clarify, if true, that Profusa&#8217;s Lumee Oxygen and Glucose
              products involve the permanent injection of a hydrogel sensor in subcutaneous tissue. Please also balance your disclosure in the Summary and throughout the prospectus to clarify that Profusa sells its oxygen sensor for research use only (RUO)
              applications in animal models and <font style="font-style: italic;">in vitro </font>testing and that Lumee Glucose is currently an investigative device for research use only.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page 1 to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Interests of Certain Persons in the Business Combination, page 4</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e4836cd383a4e7f9209fb3a07bc7632" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">10.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure that NorthView&#8217;s directors will not receive reimbursement for any out-of-pocket expenses incurred by them on incident to identifying, investigating and consummating a business combination.
              Please revise your disclosure to include the current value of loans extended, fees due, and out-pocket-expenses for which the Sponsor and its affiliates are awaiting reimbursement, including any working capital loans.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page 6 to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1ba74130067b4457a4ab57caea354a37" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">11.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We refer to your disclosure on page 5 that I-Bankers and Dawson James are entitled to receive a fee of $6,986,250 in connection with the business combination, which appears to suggest that underwriting fees
              remain constant and are not adjusted based on redemptions. Revise your disclosure to disclose the effective underwriting fee on a percentage basis for shares at each redemption level presented in your sensitivity analysis related to dilution.
              In this regard, we refer to your disclosure on page 167 that the underwriting fee is equal to 3.68% of the gross proceeds of the public offering.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 6 and 172 to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Impact of the Business Combination and Convertible Securities on New Profusa&#8217;s Public Float, page 6</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze764c03982e34906816fc707ec98c93e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">12.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note that you plan to arrange to sell additional securities to raise funds to satisfy the minimum cash required to complete the business combination transaction after returning funds to redeeming stockholders
              under the maximum redemption scenario. Please clarify the current status of discussions and negotiations regarding the contemplated PIPE investment. Revise the disclosure to discuss the key terms of any convertible securities and to disclose
              the potential impact of those securities on non-redeeming shareholders, as applicable.&#160; To the extent that negotiation and marketing processes for a PIPE are ongoing, please disclose material details of those processes, including who selected
              the potential PIPE investors, the relationships the PIPE investors have to NorthView, the Sponsor, Profusa and their affiliates, and the placement agent and how the terms of the PIPE transaction were determined, as applicable.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page 7 to include the requested information.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 4<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z19acd1905d6f4053a30ab1c0ddd28ad6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">13.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please highlight material differences in the terms and price of securities issued at the time of the IPO as compared to private placements contemplated at the time of the business combination. Disclose if the
              SPAC&#8217;s sponsors, directors, officers or their affiliates will participate in the private placement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page xv to include the requested information. The Company supplementally advises the staff that the terms of any private placement have not been agreed to as of the
      date hereof, and we further represent that such terms will be disclosed in a subsequent amendment to the prospectus/proxy statement.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>We depend upon third-party suppliers and outsource to other parties..., page 31</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze3bed86c17ba41d0957d5bd373cc8746" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">14.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your risk factor disclosure that you rely on single and/or sole sources for certain components and materials used in manufacturing your products. Please expand your disclosure to discuss your sources and
              availability of raw materials and the names of any principal suppliers. See Item 101(h)(4)(v) of Regulation S-K.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page 33 to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Activities taken by existing NorthView&#8217;s stockholders to increase the likelihood of approval of the business..., page 63</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z475836c58e7745168ec2ac32ac355806" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">15.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note disclosure here that at any time prior to the special meeting, the Sponsor, NorthView&#8217;s officers and directors, advisors or any of their respective affiliates and/or their respective affiliates may
              purchase shares from institutional and other investors who vote, or indicate an intention to vote, against the business combination proposal, or execute agreements to purchase shares from such investors in the future, or they may enter into
              transactions with such investors and others to provide them with incentives to acquire shares of NorthView common stock. You further state that the purpose of the share purchases could be to vote in favor of the business combination. Please
              provide your analysis on how such purchases comply with Rule 14e-5.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 69 to address the Staff&#8217;s comment.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>The Background of the Business Combination, page 95</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbed0828d75684d5fb194fcbd8b3b29df" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">16.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure on page 97 that NorthView engaged in detailed due diligence and discussions with eight other potential targets and delivered letters of intent to two potential business combination
              targets, other than Profusa. Please expand your disclosure of these eight potential business combination targets the NorthView Board considered and discuss the NorthView Board&#8217;s reasons in reaching its conclusions not to pursue each of the
              potential business combination target.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 100 through 104 to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z85890b0502fa4b4995969d7de3a1e5a7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">17.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please identify the individuals and/or parties who participated in the meetings, discussions and negotiations described throughout this section. By way of example only, please identify the representatives of
              NorthView and Profusa and their advisors who participated in negotiations related to the merger agreement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 100 through 104 to include the requested information.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 5<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Financial Projections, page 102</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za9b14a5b484e4a7f930c7778b2749e8d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">18.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note that the only revenue recorded by Profusa during the two years ended December 31, 2021 and the nine months ended September 30, 2022 was in the form of government grant revenues. The projections provided
              assume that revenue will commence in Q4 of 2022 for Lumee Oxygen and Q2 of 2024 for Lumee Glucose. In this regard, please address the following:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf6340983250245ceadaafcd364fa0d1f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please disclose whether these projections still reflect management&#8217;s views on future performance. For example, if there has been a change in circumstances which has resulted in changes to when revenue will
              commence for either product;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze68c4e3d89ba4756818792ee4c1e0c6b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please disclose the basis for providing projections for a seven year period given the limited operations of Profusa; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z60e337408457446e80e0a0946e6da33b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please explain how management and the Board considered and relied upon the projections. Explain how they assessed their reasonableness, particularly in light of the limited operations of Profusa.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We respectfully acknowledge the Staff&#8217;s comment.&#160; Profusa is currently in the process of preparing updated projections and will provide such updated projections, as well as modified disclosure in
      response to the Staff&#8217;s comment, in a subsequent amendment when the updated projections are available.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z04237ffec8e349b388bd31fa24686bda" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">19.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">The projections show significant increases in revenues from $5 million in 2023 to $73 million in 2024 well as further significant increases to $175 million in 2025 and $354 million in 2026. Given the limited
              operations of Profusa, we would expect detailed disclosures in order for an investor to understand the reasonableness of the assumptions underlying the projections as well as the inherent limitations of the projections. In this regard, please
              address the following:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za27c3f7b63e340b0b0d1d99999067b3d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please separately identify the projected revenue estimates for Lumee Oxygen and Lumee Glucose for each year. Specifically for each product, please also discuss all material assumptions and the basis for those
              assumptions used to develop the projections, including when each projection assumes each product candidate will obtain regulatory approval by market, the length of time from approval to commercial availability, assumptions about market
              acceptance / penetration rates, market growth rates, the impact of competition, and any other factors or contingencies that would affect the projections from materializing. To the extent the projections are based on multiple scenarios,
              discuss that fact, identify the various scenarios used, and how each scenario was weighted;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd779da7a7e684a16810f7ef4c73445be" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Lumee Glucose revenue numbers are cross-referenced and viability-checked with the patient launch numbers for an existing competitor Abbott. The patient numbers for Abbott at the end of 2018 after their launch in
              2017 are also disclosed. Please further clarify how the numbers for Abbott were relied upon in coming up with these projections. Please address the reasonableness of referencing Abbott&#8217;s patient launch numbers and address any limitations in
              relying on these numbers given that Abbott is an established, well-known international company with $43B in revenues; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e98188504314b90a99f648861521659" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note the discussion of various collaborations and partnerships which are expected to increase revenue.&#160; Please further clarify the assumed impact of these on the projected revenue amounts and your basis for
              these assumptions.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We respectfully acknowledge the Staff&#8217;s comment.&#160; Profusa is currently in the process of preparing updated projections and will provide such updated projections, as well as modified disclosure in
      response to the Staff&#8217;s comment, in a subsequent amendment when the updated projections are available.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 6<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5a38bdff53504e9bb32f5903fe0ddb2c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">20.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please expand your disclosures to define EBITDA and Net Cash Flows and provide detailed information as to how these financial measures were calculated. Provide a description of the GAAP financial measures to
              which these measures are most closely related and explain why non-GAAP financial measures were used instead of GAAP measures.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We respectfully acknowledge the Staff&#8217;s comment.&#160; Profusa is currently in the process of preparing updated projections and will provide such updated projections, as well as modified disclosure in
      response to the Staff&#8217;s comment, in a subsequent amendment when the updated projections are available.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z59546838c86c433bb12b8d964d60a26e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">21.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please disclose the material assumptions underlying your projected EBITDA and Net Cash Flow and explain the basis for those assumptions. This disclosure should include a discussion of the material underlying
              projected cost of sales, operating expenses and other expenses which are reflected in the determination of EBITDA and net cash flow.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We respectfully acknowledge the Staff&#8217;s comment.&#160; Profusa is currently in the process of preparing updated projections and will provide such updated projections, as well as modified disclosure in
      response to the Staff&#8217;s comment, in a subsequent amendment when the updated projections are available.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Material U.S. Federal Income Tax Considerations, page 119</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7030db6d6f6b4be785e5fb5d34d1cc5e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">22.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please revise to include a tax opinion covering the material tax consequences of the redemption and state that the disclosure in this section represents the opinion of counsel. Please also remove language stating
              that &#8220;generally&#8221; certain tax consequences will apply or assuming certain consequences. For further guidance, see Staff Legal Bulletin No. 19.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: ArentFox Schiff LLP is providing, on supplemental basis, a draft opinion as <u>Exhibit A</u> hereto that is intended to comply with the requirements of the referenced Staff Legal Bulletin. We confirm
      that final, executed opinion will be filed as exhibits to the Registration Statement prior to effectiveness.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Unaudited Pro Forma Condensed Combined Financial Information Description of the Transactions, page 126</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8960e5f73f7d486b99744cb0f88b6555" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">23.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">The second bullet on this page indicates that Profusa&#8217;s equityholders and holders of convertible promissory notes will receive or have the right to receive an aggregate of 15.5 million shares of New Profusa
              common stock.&#160; Please clarify in your disclosures how this 15.5 million shares corresponds to the shares of New Profusa&#8217;s common stock shown under the no redemption and maximum redemption scenarios. Also, explain why the number of shares
              issued to the Profusa equity holders under the no redemption scenario differs from the number of shares issued under the maximum redemption scenario.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 134 to 136 to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z05dfd71898fa4ed29085dd1c93a57886" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">24.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">With reference to the key terms of Merger Agreement as set forth on page 99, please reconcile the disclosures surrounding the financial inducement to meet minimum cash requirements as presented in the 3rd bullet
              on page 99 to your disclosures on page 127 which indicates that the Sponsor has agreed to forfeit up to 1,040,000 shares of NorthView common stock.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 134 to 136 to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Accounting for the Business Combination, page 127</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9c0bc27fbd294495a1b10383298feed6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">25.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note that the merger will be accounted for as a reverse recapitalization with Profusa being the accounting acquirer. With reference to the fact that Profusa shareholders will only have a 35.9% ownership
              interest in the combined entity in the no redemption scenario, please provide the basis for this determination. Refer to ASC 805-10-25-5 and 810-10-15-8.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin: 0px 0px 0px 40.5pt;"><u>RESPONSE</u>: The Company respectfully advises the Staff that subsequent to the filing of the initial Registration Statement, the Company experienced stockholder redemptions such that Profusa shareholders are
      expected to have a 61.0% ownership interest in the combined entity assuming a no redemption scenario. Accordingly, under either scenario, Profusa shareholders will have majority ownership of New Profusa, and, therefore, reverse recapitalization
      treatment is appropriate.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 7<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5982220feb7c46fd9bd78f8bc46fbb6a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">26.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note that the unvested Milestone Earnouts, Sponsor Inducement Recoupment Earnouts and Profusa Inducement Recoupment Earnouts are expected be classified as equity measured at fair value as at the date of the
              Merger, with no subsequent remeasurement at each reporting date. Please expand your disclosures to address the primary factors which led to the equity classification determination.&#160; Refer to ASC 480 and 815-40.&#160;&#160; Also address your
              consideration of whether the arrangements were compensation arrangements under ASC 718. Finally, disclose the fair value of these earnouts and how such fair value was determined.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 136 and 137 to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Unaudited Pro Forma Condensed Combined Balance Sheet, page 130</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z42433056396e4782a827fb1552a994df" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">27.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note that one of the conditions to closing the business combination is that cash on hand will not be less than $15,000,000. Please disclose this condition and clarify how this condition is met under the
              maximum redemption scenario given the $5,937,000 pro forma cash balance as of September 30, 2022.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: The Company respectfully advises the Staff that additional PIPE financing, as included in the revised pro forma condensed combined balance sheet, is expected to enable the Company to meet the minimum
      cash requirement of $15,000,000. We have also amended the disclosures on pages 139 and 145 to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0d7a9a3c28a847779a53e25557c0bf22" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">28.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note that NorthView&#8217;s and Profusa&#8217;s respective obligations to consummate the business combination are conditioned on NorthView having at least $5,000,001 of net tangible assets as of Closing. Please expand
              your disclosures to discuss this condition, quantify the net tangible assets under each scenario and indicate how you calculated such amounts.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page 136 to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Unaudited Pro Forma Condensed Combined Statements of Operations, page 132, page 132</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z947baa32c08a48608a98813be24dbac1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">29.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Given the conversion of the convertible notes payable in adjustment (N), it is not clear why there is no corresponding adjustment to interest expense. Please advise or revise as necessary. Please also address
              your consideration of adjusting for the gain (loss) on change in the fair value of derivative liabilities which appear to relate to these same notes payable.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: The Company respectfully advises the Staff that until their modification on September 27, 2022, Profusa&#8217;s Senior Notes did not contain a provision under which these notes would be convertible into
      common shares upon a deSPAC transaction. The Company determined that in absence of a provision for conversion of the Senior Notes upon a deSPAC transaction, the Senior Notes would remain repayable in cash, based on their terms, rather than converted
      into common shares of the Company upon a deSPAC transaction. Accordingly, the Company concluded that it is appropriate to not include adjustment for the interest expense related to the Senior Notes until their modification on September 27, 2022. We
      also advise that the interest expense incurred with respect to the Senior Notes between September 27, 2022 and September 30, 2022 was immaterial. We included a pro forma adjustment (CC) to the condensed combined statement of operations for the year
      ended December 31, 2022 on page 141 and 143 that eliminates the interest expense incurred on Profusa&#8217;s convertible notes following their modification which adds a provision for conversion of these notes upon a deSPAC transaction.</div>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;">We also respectfully advise the Staff that both the Junior Notes and Senior Notes were subsequently modified, on November 7, 2022, to include automatic conversion of all convertible notes payable into common shares of
      the Company at a stated price, and, at the same time, removed the feature that gave rise to the derivative liability associated with the Senior Notes. Accordingly, no adjustments with respect to the derivative liabilities are necessary for the
      unaudited pro forma condensed combined balance sheet and statement of operations for the year ended December 31, 2022.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 8<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze04f8d73973e484fa971f0bc61f1ff0e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">30.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please help us understand why the proforma combined columns, which assume that the transaction took place on January 1, 2021, reflect basic and diluted weighted average shares outstanding, common stock subject to
              possible redemption instead of just basic and diluted weighted average shares outstanding, common stock. It would appear that there would no longer be common stock subject to redemption.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have corrected the presentation of weighted average shares outstanding in the proforma combined columns on page 141.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0d5c0aecefdc417d8655d27c04d4abd6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">31.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note that the weighted average shares outstanding of Profusa common stock used for purposes of determining net loss per share amounts are not the same as the total shares expected on the closing of the
              Business Combination as reported on page 129. We also note the amount of issued and outstanding shares referenced in your pro forma common stock balance sheet line item on page 138 is also different. Please explain these apparent
              discrepancies or revise your disclosures accordingly.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: The Company respectfully advises the staff that the total shares expected on the closing of the Business Combination include common shares previously issued to a shareholder of Profusa upon early
      exercise of an option in exchange for a non-recourse promissory note. Since such shares are legally outstanding, they are included in the total share count upon the closing of the Business Combination. However, for accounting purposes, the issuance
      of common stock upon early exercise of options is disregarded, because the shares are issued in exchange for a non-recourse promissory note, and such shares are not included in the calculation of loss per share. Accordingly, the shares issued upon
      early exercise of options in exchange for promissory note are excluded from the calculations of pro forma net loss per share and book value per share..</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb4e88cf72bad41239a761881cf02769a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">32.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We refer you to adjustment DD. With reference to the Milestone Earnouts and Profusa Inducement Recoupment terms and conditions, please provide your basis for recognizing issuances under these agreements.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: The Company respectfully advises the staff that the Company considers the Milestone Earnouts and Profusa Inducement Recoupment Earnouts to represent instruments that will be automatically issued to the
      shareholders of Profusa upon closing of the Business Combination, resulting in certain value (embedded in these instruments) being transferred from Profusa to its shareholders. Because Profusa&#8217;s shareholders are automatically entitled to these
      instruments upon closing of the Business Combination, the Company considers that these instruments will have been issued to the shareholders of Profusa immediately upon the closing of the Business Combination. The Company also believes that within
      the context of reverse recapitalization, such transfer of value from Profusa to its shareholders represents a deemed dividend.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Comparative Per Share Data, page 137, page 137</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z30bf05f7be9144cc9b099c81a42ed367" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">33.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">In regards to your table, please address the following:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc7cbed02b0cd469599c4b06963c995e2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Certain amounts do not agree to the amounts presented on your pro forma statements of operations beginning on page 132. Please advise or revise as necessary. For example, there appear to be differences in the
              NorthView&#8217;s historical net income (loss) per share amounts as well as the pro forma combined weighted average shares outstanding;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8aee08c8842240b99eee0f87ee9075cd" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please explain how you determined the exchange ratio for purposes of determining the Profusa equivalent pro forma per share data amounts; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaee41e7fb2c14bb8bd3e6f8b196ea198" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 42.3pt;"><br>
          </td>
          <td style="width: 19.6pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">It is not clear what the weighted average shares outstanding amounts of 8,381,948 under the pro forma equivalent pro forma per share data represents. Please revise or advise as necessary.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have corrected the amounts presented on page 145 to align with those included in the pro forma statement of operations on page 141 in response to the Staff&#8217;s comments. We also respectfully advise
      the Staff that the same exchange ratio is applied in the revised comparative per share data for determining the Profusa equivalent pro forma per share data amounts as was used for calculating the conversion of Profusa&#8217;s common stock and preferred
      stock upon the closing of the Merger. We have also revised footnote 4 to the comparative per share data table on page 146 to provide an explanation for the calculation of the Profusa equivalent of weighted average shares outstanding of New Profusa
      common stock, basic and diluted.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 9<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Profusa&#8217;s Business, page 171</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdc686d25af754c808149e7b730a9118d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">34.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please clarify the meaning of scientific or technical terms the first time they are used in order to ensure that lay readers will understand the disclosure. For example, please briefly explain what you mean by
              limb ischemia, perfusion, Rutherford Scale, interstitial, tomographic, angiographic, thermistor, oximetry, hemodynamic and diabetes mellitus.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have revised the disclosures on pages 2, 183, 186, 189 and 195 in response to the Staff&#8217;s comments.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8137fee13c56406683d43940e658a26c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">35.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your prominent disclosure on page 171 of &#8220;sophisticated investors from Asia who already see the far-reaching benefit of Profusa&#8217;s platform&#8221; and have invested in its development to date. Please expand your
              disclosure to identify such investors, describe their investments in the company and clarify the current status of discussions and negotiations and any agreements such investors have entered into any agreements with Profusa. We refer to your
              disclosure on 206 relating to a binding term sheet for the APAC Joint Venture with certain institutional investors.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page 179 to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf6f7b58f794f415a8cf3fc79a497b523" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">36.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure on page 185 that your products are currently categorized as Class III devices. In an appropriate section of your prospectus, please describe the briefly discuss the FDA&#8217;s regulation of
              medical devices and the classification of medical devices into one of three classes (Class I, Class II and Class III) depending on its level of risk.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have revised the disclosures on pages 196 and 197 to included the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcb8ec8af58f44bf9ace2cd5389722332" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">37.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We refer to your disclosure on page 184 that Profusa anticipates initiating its commercialization efforts for its Lumee Oxygen product beginning in early 2023 followed by FDA approval of Lumee Glucose in 2024.&#160;
              You also disclose on page 171 that Profusa&#8217;s business plans are anchored by the &#8220;near-term launch&#8221; of Lumee Oxygen and refer to the company as a commercial-stage digital health and medical technology company on page 192. Please revise to
              disclose that Profusa&#8217;s business plans for its two lead products in the US remain subject to regulatory approval. Please also balance your disclosure with equally prominent disclosure of the limitations and challenges Profusa faces in
              implementing its business strategy and gaining regulatory acceptance, including the implications if the company does not receive approval under the Section 510(k) regulatory pathway.&#160; We also note your disclosure that Profusa has not yet
              commercialized its Lumee Oxygen product in Europe since receiving its CE Mark in January 2020, that Profusa&#8217;s Lumee Oxgyen recently completed the pilot phase of its clinical study, and that the company&#8217;s oxygen sensor and glucose monitoring
              device are currently for research use only applications.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have revised the disclosures on pages 180, and 196 to 202 in response to the Staff&#8217;s comments.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Short-Term Opportunity with Lumee Oxygen and Lumee Glucose, page 177</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze7ea954028a449dd8d6dc057dc808490" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">38.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure that the total market size of telemedicine platforms has increased to over $80 billion in 2021 with the market for remote coaching platforms growing to just under $14 billion. Please
              revise to disclose the estimated total addressable market for glucose and oxygen monitoring devices in the U.S. and Europe.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on page 185 and 186 to include the requested information.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 10<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Profusa&#8217;s Product Path and Clinical Programs, page 179</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc0a5d3a860914db6a6082b682c6f112f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">39.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure that no device-related serious adverse events were observed with respect to your Lumee Oxygen and Lumee Glucose clinical studies. You also disclose on page 184 that all reported adverse
              events related to Lumee Glucose had been considered expected. For each clinical study, please disclose the number and type of adverse events observed and whether any subjects explanted the devices following the trials.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 188 to 190 to include the requested information.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9a4605f61d4342798f2e738d366eda87" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">40.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We refer to your disclosure on page 180 that you are developing a next generation prototype of Lumee Oxygen in various anatomical locations and usability data in healthy adult volunteers in daily life. Please
              expand your disclosure of the new generation prototype and disclose whether you expect such next generation device to require a prior de novo classification grant, 510(k) clearance or a PMA from the FDA.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: Profusa respectfully advises the Staff that no design changes to Lumee Oxygen will occur prior to regulatory approval of the current existing device in the United States.&#160; Following regulatory
      approval, Profusa will evaluate design changes for a next generation device and determine at that time what type of regulatory clearance is required.&#160; We have revised the disclosure on page 189 to clarify.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Lumee Glucose Clinical Study History, page 181</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdc49d27cfe3b4b5982107e4a24ac06c1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">41.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please expand your disclosure relating to the Lumee Glucose studies to clarify whether the studies were powered for statistical significance; discuss the p-values and statistical significance, as applicable, and
              the age range of participants; and revise your characterizations for the clinical studies to discuss the data, rather than drawing conclusions from the results. Please also explain the difference color coding used to label sections A through
              E in the graphics on pages 183 and 184.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have amended the disclosures on pages 190 to 193 to include the requested information.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Commercial Strategy, page 183</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z408895ef851a47f78ae8cfda460fc4d4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">42.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure that Profusa has been featured in more than 25 publications in peer-reviewed journals and public presentations of its science and product applications to date. Please clarify whether
              Profusa commissioned or if any Profusa employees were involved in such publications and presentations.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: Profusa respectfully advises the Staff that none of these publications were commissioned by Profusa.&#160; Certain of these publications involved one or more Profusa service providers as co-authors, but
      none of such publications were written at the direction of Profusa management.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb560f5649a1e49a6b31d9cd1eaae7b98" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">43.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your references to your investment in and access to key opinion leaders on pages 184 and 192. We also refer to disclosure that you will sell your products directly to facilities based on the endorsement
              of key opinion leaders and that certain key opinion leaders have already used Lumee Oxygen on a trial basis in Europe. If material, please include disclosure that describes the role or function of your key opinion leaders, how the key opinion
              leaders are selected and compensated and whether there are any rules or procedures governing such key opinion leaders.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: Profusa respectfully advises the Staff that Key Opinion Leaders were selected based on their knowledge of relevant subject matter, but also with regards to their level of influence in promoting
      emerging breakthrough technologies, such as Profusa&#8217;s, within the larger academic (PAD and diabetes researchers) or professional communities (vascular surgeons, radiologists, diabetologists, endocrinologists) that are pertinent to successful product
      launch.&#160; Key Opinion Leaders have, in some cases, received equity in Profusa as part of a stock option plan, though this is so far limited to U.S.-based physicians who provided their expertise with regards to Lumee Oxygen only.&#160; Profusa does not
      believe these matters are material to an investor&#8217;s understanding of Profusa&#8217;s business.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><img src="ny20006207x3_logo.jpg"></td>
            <td style="width: 50%; text-align: right; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">May 11, 2023</div>
              <div style="font-family: 'Times New Roman',Times,serif;">Page 11<br>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Intellectual Property, page 185</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeb1317f9d2e247f690256a961b005118" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">44.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We note your disclosure that Profusa has 22 issued U.S. patents, 69 rest-of-world patents, 14 pending U.S. patents and 61 pending rest-of-world patents.&#160; Please revise to identify for each material patent and
              pending patent, as applicable, the scope and technology of each patent or patent application, whether the patents are owned or licensed, the type of patent protection, jurisdiction and expiration dates. In this regard, consider using tabular
              disclosure in addition to the narrative for ease of use.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have revised the disclosures on page 194 and 195 in response to the Staff&#8217;s comments.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Competition, page 186</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1dd0af600b614072bed0371429e6d720" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">45.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">We refer to your disclosure relating to your competitors who have also developed digital angiography devices and continuous glucose monitoring devices. Please disclose whether any of your competitors have digital
              health devices that also provide biochemical data in real time. You also disclose on page 177 that the second phase of launching Profusa&#8217;s glucose product for the diabetes market will expand beyond the current Type 1 diabetes population to
              include patients with Type 2 diabetes and the prediabetes populations. Please disclose whether any of your competitors have developed or are developing glucose monitoring devices targeting Type 2 diabetes and prediabetes populations as well.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We have revised the disclosures on page 195 in response to the Staff&#8217;s comments.</div>
    <div><br>
    </div>
    <div style="margin-left: 7pt; font-weight: bold;"><u>Beneficial Ownership, page 204</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z47cf95b9e13e43bea0b22b1a03c7e2d2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9pt;"><br>
          </td>
          <td style="width: 31.8pt; vertical-align: top; font-weight: bold;">46.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Please revise to identify the natural persons who are the beneficial owners of the shares held by BC hSensor Limited, Carbis Bay Limited and Tasly (International) Healthcare Capital Company Limited.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="margin-left: 40.5pt;"><u>RESPONSE</u>: We respectfully acknowledge the Staff&#8217;s comment.&#160; Profusa is currently in the process of collecting the requested information from these stockholders and will provide such information in a subsequent
      amendment. <br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center;">* * * * *</div>
    <div><br>
    </div>
    <div style="text-align: justify;">If you have any comments or questions please feel free to address them to the undersigned. You can reach me at my office at 202-724-6848, on my mobile telephone number at 202-415-8300, and via email at
      ralph.demartino@afslaw.com.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Thank you in advance for your prompt attention to this Correspondence and to the Amendment. We expect to file a Rule 461 request as soon as the Staff confirms that it has no further comments.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Respectfully submitted,</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><img src="ny20006207x3_image01.jpg" height="35" width="155"></div>
    <div><br>
    </div>
    <div style="text-align: justify;">Ralph V. De Martino</div>
    <div><br>
    </div>
    <div style="text-align: justify;">RVD/mc</div>
    <div style="text-align: justify;">cc: Jack Stover</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Exhibit A</u></div>
    <div><br>
    </div>
    <div style="text-align: justify;">[&#9679;], 2023</div>
    <div><br>
    </div>
    <div style="text-align: justify;">NorthView Acquisition Corp.</div>
    <div style="text-align: justify;">207 West 25th St, 9th Floor</div>
    <div style="text-align: justify;">New York, NY 10001</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt; font-weight: bold;">Re:&#160; Registration Statement on Form S-4</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">We have acted as counsel to NorthView Acquisition Corp., a Delaware corporation (the &#8220;<font style="font-weight: bold;">Parent</font>&#8221;), in connection with the negotiation and execution of Merger
      Agreement and Plan of Reorganization, dated as of November 7, 2022, by and among Parent, NV Profusa Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (&#8220;<font style="font-weight: bold;">Merger Sub</font>&#8221;), and
      Profusa, Inc., a California corporation (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;), pursuant to which Merger Sub will merge with and into the Company with the Company surviving
      the merger (the &#8220;<font style="font-weight: bold;">Merger</font>&#8221;). Reference is made to the Registration Statement on Form S-4 of Parent, including joint proxy statement/prospectus forming a part thereof, initially filed with the Securities and
      Exchange Commission under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;), on [&#9679;] (as amended or supplemented through the date hereof, the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;),


      relating to the Merger. Capitalized terms used but not defined herein have the meaning given to such terms in the Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">In providing our opinion, we have examined the Agreement, the Registration Statement, and such other documents as we have deemed necessary or appropriate for purposes of this opinion (collectively,
      the &#8220;<font style="font-weight: bold;">Documents</font>&#8221;).&#160; In our examination of the Documents, we have assumed, without independent verification, (i) their completeness and authenticity, (ii) that each of the Documents has been or will be duly
      authorized and executed in the form as examined by us and will be binding upon all parties thereto, (iii) the parties to each agreement have complied, and will comply, with all of their respective covenants, agreements and undertakings contained
      therein, (iv) that the transactions provided for by each agreement were and will be carried out in accordance with their terms, (v) that the Merger will be consummated in compliance with the Agreement, and (vi) that the parties to the Merger
      Agreement have no plan or intention to waive or modify, and have not waived or modified, any of the material terms or conditions in the Agreement.&#160; We are relying upon the accuracy of any representations or statements made that are qualified by the
      maker&#8217;s knowledge or belief as if such representations or statements were made without such qualification. We have also assumed that as to all matters for which a person or entity has represented that such person or entity is not a party to, does not
      have, or is not aware of, any plan, intention, understanding, or agreement, there is no such plan, intention, understanding, or agreement. We have not been asked to and have not attempted to verify any facts, information, warranties or
      representations (collectively &#8220;<font style="font-weight: bold;">statements</font>&#8221;) through independent investigation and are assuming that each is true, correct and complete as of the date hereof and that no actions inconsistent with such statements
      have occurred or will occur.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Based on and subject to the foregoing, the qualifications, exceptions, assumptions, qualifications and limitations contained herein and in the Registration Statement, it is our opinion that the
      statements in the Registration Statement set forth under the caption &#8220;<font style="font-style: italic;">Material U.S. Federal Income Tax Consequences&#8212;Tax Consequences to Holders Electing to Exercise Redemption Rights</font>,&#8221; to the extent that they
      constitute descriptions or summaries of material U.S. federal income tax considerations for holders of public shares of NorthView Common Stock with respect to the exercise of their redemption rights, are accurate in all material respects.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">We express no opinion on any issue relating to the tax consequences of the transactions contemplated by the Agreement or the Registration Statement other than the opinion set forth above, nor do we
      express any opinion on any other issue relating to the Company or to any investment therein or under any other law.&#160; In addition, we express no opinion as to the tax treatment of any conditions existing at the time of, or effects resulting from,
      transactions that are not specifically addressed herein.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Our opinion is based upon the Code, the Income Tax Regulations promulgated thereunder, and administrative and judicial determinations, all as of the date hereof and all of which are subject to change
      either prospectively or retroactively.&#160; In addition, our opinion is based upon our knowledge of the facts as of the date hereof. If (i) the relevant facts at the time of closing differ from those represented to us in the Representation Certificates
      or reflected in the Documents, (ii) the Merger is completed under terms not contained in the Agreement, (iii) our assumptions prove to be untrue, or (iv) the existing authorities are modified by legislative, administrative or judicial action, our
      conclusions may differ and our opinion may not be relied upon. Furthermore, by rendering this opinion, we undertake no responsibility to provide a revised opinion or other advice, and we assume no duty to communicate with you with respect to any new
      developments in the application or interpretation of the federal income tax laws.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">You should be aware that no ruling has been sought or obtained from the Internal Revenue Service (the &#8220;<font style="font-weight: bold;">Service</font>&#8221;) as to the federal income tax consequences of
      any aspect of the exercise of redemption rights by holders of public shares of NorthView Common Stock and that our opinion is not binding on the Service. You should also be aware that there can be no assurance, and none is hereby given, that the
      Service will not take a position contrary to the position reflected in our opinion, or that our opinion will be upheld by the courts if challenged by the Service.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the use of our name in the &#8220;<font style="font-style: italic;">Material U.S. Federal Income Tax
        Consequences</font>&#8221; section in the Registration Statement. In giving such consent, we do not thereby concede that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of
      the Securities and Exchange Commission thereunder.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Very truly yours,</div>
    <div><br>
    </div>
    <div style="text-align: justify;">ArentFox Schiff LLP</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ny20006207x3_image01.jpg
<TEXT>
begin 644 ny20006207x3_image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X -@# 2(  A$! Q$!_\0
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M%&NZ29ST1%'+,?3^E9=GHEQJ=RFI^(@DDJMNM[ '=#:^A/\ ?D_VCT_AQU(
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MQ<70\V28G[[$MG!8\G&*9=?#/PG=Q31'3/*CEYV0S.B(^,;U0':K\#Y@,\4
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7 "BBB@ HHHH **** $YSVQVHHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ny20006207x3_logo.jpg
<TEXT>
begin 644 ny20006207x3_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  Y (<# 2(  A$! Q$!_\0
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M/_1:U5\=?\@1?^NJ_P C6UI__'A;?]<E_D*EOW;%J-IMG@_P&(/QB^(^"/\
M7-_Z.>F? 8@_&;XBX(_UK_\ H]J]9\+_ /(PZQ_O'_T(TGA?_D8M7_WC_P"A
M&K<MR(PM8\KE(_X:\C&1G[%T_P"W<UT?[49Q\*+C/'^EP?\ H5=DW_(_#_KG
M_P"R5<\;?\@)O^NBTN;5,?)[LEW(/AGS\._#./\ H&V__HM:Z6J>C?\ ()LO
:^N*?R%7*A[FL=%8****0PHHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
